Liran Belenzon, Co-founder and CEO of BenchSci, is a trailblazer in applying AI to drug discovery and R&D. He discusses how AI transformations are tackling the complexities of disease biology, paving the way for more efficient workflows. Liran highlights the significance of knowledge graphs and multimodal AI in enhancing research speed and quality. He emphasizes the need for flexible drug discovery processes and the importance of adapting budgets to harness AI’s full potential, balancing innovation with cost-effectiveness.